Neuropharmacology and analgesia
Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties

https://doi.org/10.1016/0014-2999(96)00086-6Get rights and content

Abstract

In vivo microdialysis measuring 5-hydroxytryptamine (5-HT) levels in the ventral hippocampus of chloral hydrate-anaesthetised rats was used to characterise further the recently described 5-HT1A receptor antagonists (S)-WAY100135 ((S)-N-tert-butyl-3-(4-(2-methoxyphenyl)piperazine-1-yl)-2-phenylpropanamide) and WAY100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide). In addition, binding experiments were performed to determine the affinity of the compounds for 5-HT1A receptors and for α1-adrenoceptors. Both (S)-WAY100135 and WAY100635 exhibited high affinity for 5-HT1A receptors and moderate affinity for α1-adrenoceptors. The effects of (S)-WAY100135 (0.63–20 mg/kg) and of WAY100635 (0.0025–0.16 mg/kg) on 5-HT levels were examined alone, and in combination with the 5-HT1A receptor agonist, (±)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Both compounds dose-dependently reversed the 8-OH-DPAT-induced decrease in extracellular 5-HT levels with ED50 values of approximately 3.3 and 0.03 mg/kg, respectively. When given alone, WAY100635 did not alter 5-HT levels. (S)-WAY100135, however, induced, by itself, a transient but significant and dose-dependent decrease in 5-HT levels. WAY100635 (0.16 mg/kg) prevented the decrease induced by (S)-WAY100135 (10 mg/kg), but did not reverse the decrease induced by the α1-adrenoceptor antagonist, prazosin (0.16 mg/kg). These results are further evidence that (S)-WAY100135 may modulate the release of 5-HT by acting as a partial agonist at somatodendritic 5-HT1A receptors. In contrast, WAY100635 acts as a potent and selective 5-HT1A receptor antagonist.

References (30)

  • L. Rouquier et al.

    α1-Adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: A microdialysis study

    Eur. J. Pharmacol.

    (1994)
  • C. Routledge et al.

    Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: An in vivo microdialysis study

    Eur. J. Pharmacol.

    (1993)
  • T. Sharp et al.

    Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378

    Eur. J. Pharmacol.

    (1990)
  • M.-B. Assié et al.

    Effects of (S)WAY 100135 on 5-HT levels in the ventral hippocampus of anaesthetized rat as measured by in vivo microdialysis

  • M.-B. Assié et al.

    WAY 100635 reverses the decrease in 5-HT levels produced by the putative 5-HT1A antagonist, WAY 100135

    Soc. Neurosci. Abstr.

    (1995)
  • Cited by (88)

    • The Role of 5-HT1A Receptor, and Nausea and Vomiting Relief by Cannabidiol (CBD), Cannabidiolic Acid (CBDA), and Cannabigerol (CBG)

      2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment
    • Extending therapeutic use of psychostimulants: Focus on serotonin-1A receptor

      2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry
    • Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats

      2012, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      Secondly, the dose of SYA013 used by us (0.08 mmol/kg) is smaller than that used by Depoortere (0.1 mmol/kg) for F15063. Indeed, others have used smaller doses (0.16 mg/kg) of WAY100,635 to reverse 8-OH-DPAT effects (Assie and Koek, 1996). A new instrument, the Catalepsy Test Chamber (Med Associates, Inc., St. Albans, VT), was used to assist in performing the classic catalepsy bar test with rats.

    • Mapping of CBV changes in 5-HT1A terminal fields by functional MRI in the mouse brain

      2011, European Neuropsychopharmacology
      Citation Excerpt :

      However, other studies using electrophysiological recording in vitro, demonstrated that WAY-100635 blocks the effect of 5-HT agonists in a dose-dependent fashion at both, post-synaptic 5-HT1A receptors in ascending 5-HT projection areas such as cingulate cortex, hippocampus, and amygdala, and somatodendritic 5-HT1A receptors located on dorsal raphe nucleus 5-HT neurons, but cannot activate the 5-HT1A receptor on its own. Studies in anesthetized animals further demonstrated that WAY-100635 does not increase extracellular 5-HT levels (Assié and Koek, 1996) or serotonergic firing in dorsal raphe nucleus (Fletcher et al., 1996). From these findings, we speculate that the weak CBV decrease elicited by WAY-100635 is independent of the 5-HT1A receptor.

    View all citing articles on Scopus
    View full text